Two Sigma Advisers
GYRE icon

Two Sigma Advisers’s Gyre Therapeutics GYRE Stock Holding History

Two Sigma Advisers’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,747
Closed -$7K – 2591
2022
Q3 		$7K Sell
1,747
-1,333
-43% -$16.9K ﹤0.01% 2494
2022
Q2 		$41K Sell
3,080
-520
-14% -$3.46K ﹤0.01% 2499
2022
Q1 		$18K Sell
3,600
-20,680
-85% -$102K ﹤0.01% 2670
2021
Q4 		$166K Buy
24,280
+10,013
+70% +$171K ﹤0.01% 2334
2021
Q3 		$440K Sell
14,267
-6,120
-30% -$201K ﹤0.01% 1978
2021
Q2 		$662K Sell
20,387
-12,933
-39% -$444K ﹤0.01% 1822
2021
Q1 		$1.26M Sell
33,320
-11,120
-25% -$508K ﹤0.01% 1522
2020
Q4 		$2.1M Buy
44,440
+5,440
+14% +$236K 0.01% 1232
2020
Q3 		$1.26M Buy
39,000
+600
+2% +$23.5K ﹤0.01% 1395
2020
Q2 		$1.69M Buy
38,400
+12,653
+49% +$594K 0.01% 1289
2020
Q1 		$844K Buy
25,747
+7,254
+39% +$333K ﹤0.01% 1577
2019
Q4 		$945K Buy
18,493
+7,160
+63% +$300K ﹤0.01% 1604
2019
Q3 		$417K Sell
11,333
-2,854
-20% -$154K ﹤0.01% 1784
2019
Q2 		$784K Sell
14,187
-466
-3% -$29.1K ﹤0.01% 1626
2019
Q1 		$891K Sell
14,653
-387
-3% -$24.9K ﹤0.01% 1578
2018
Q4 		$890K Sell
15,040
-973
-6% -$71.8K ﹤0.01% 1534
2018
Q3 		$1.29M Buy
16,013
+2,026
+14% +$161K ﹤0.01% 1407
2018
Q2 		$1.22M Buy
+13,987
New +$2.45M ﹤0.01% 1525
2015
Q1 		– Sell
-215
Closed -$446K – 2098
2014
Q4 		$446K Buy
215
+39
+22% +$75.1K ﹤0.01% 1691
2014
Q3 		$350K Buy
176
+12
+7% +$29.7K ﹤0.01% 1761
2014
Q2 		$581K Buy
164
+10
+6% +$32.6K ﹤0.01% 1561
2014
Q1 		$576K Buy
154
+2
+1% +$7.4K 0.01% 1484
2013
Q4 		$497K Sell
152
-20
-12% -$78.8K ﹤0.01% 1598
2013
Q3 		$722K Buy
172
+16
+10% +$64.4K 0.01% 1154
2013
Q2 		$524K Buy
+156
New +$594K 0.01% 1295

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Two Sigma Advisers's GYRE Position: Q4 2022 in Review

Two Sigma Advisers sold out of Gyre Therapeutics (GYRE) in Q4 2022, closing a stake of 1,747 shares — an estimated $7K sold.

Two Sigma Advisers first reported a position in GYRE in Q2 2013 and held it in 25 quarters. The position peaked at $2.1M in Q4 2020. 34 funds tracked by Wall St. Rank hold GYRE as of Q4 2022.

  • Two Sigma Advisers reported no remaining Gyre Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 1,747 Gyre Therapeutics shares in Q4 2022, an estimated $7K.
  • Two Sigma Advisers first reported a position in Gyre Therapeutics in Q2 2013 and held it in 25 quarters.
  • Two Sigma Advisers's Gyre Therapeutics position peaked at $2.1M in Q4 2020.
  • 34 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2022.

Based on Two Sigma Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.